期刊文献+

口服多西环素联合强脉冲光治疗丘疹脓疱型玫瑰痤疮的临床疗效研究 被引量:9

下载PDF
导出
摘要 目的评价口服多西环素联合强脉冲光治疗丘疹脓疱型玫瑰痤疮患者疗效。方法采用随机数字法将符合诊断标准的63名丘疹脓疱型玫瑰痤疮患者分配进入联合治疗组(31例)和对照组(32例),全部患者口服多西环素,治疗组较对照组在口服多西环素的基础上于第2周、第5周、第8周行强脉冲光治疗各一次。结果治疗8周之后多西环素联合强脉冲光治疗丘疹脓疱型玫瑰痤疮较单纯口服多西环素治疗有效率更高,停药4周后联合组有效率仍高于对照组,差异有统计学意义(P<0.05)。此外,联合治疗组持久性红斑医生评分(CEA)和患者自评分(PSA)、VISIA皮肤检测红斑绝对值均降低,差异均有统计学意义(P<0.05)。在皮肤屏障功能指标方面,联合治疗组治疗结束时皮肤经表皮失水量降低得更明显,而角质层含水量更高,差异均有统计学意义(P<0.05)。结论口服多西环素联合强脉冲光治疗丘疹脓疱型玫瑰痤疮可以提高有效率,保持更长的稳定时间,对患者面部持续性红斑改善更明显,也可改善患者皮肤屏障功能,为临床治疗丘疹脓疱型玫瑰痤疮提供更好的理论依据。
出处 《皮肤病与性病》 2021年第5期658-661,共4页 Dermatology and Venereology
基金 中山市卫健局医学科研立项“口服多西环素联合强脉冲光治疗丘疹脓疱型玫瑰痤疮的临床疗效研究”(2021J383)。
  • 相关文献

参考文献4

二级参考文献47

  • 1李铁男,刘岩.中晚期酒渣鼻最佳治疗方案的探讨[J].中国医学美学美容杂志,1996,5(3):160-162. 被引量:3
  • 2Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea[J]. Nat Med, 2007, 13(8): 975-980.
  • 3Yamasaki K, Schauber J, Coda A, et al. Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin[J]. FASEB J, 2006, 20(12): 2068-2080.
  • 4Hachem JP, Houben E, Crumrine D, et al. Serine protease sig- naling of epidermal permeability barrier homeostasis[J]. J Invest Dermatol, 2006, 126(9): 2074-2086.
  • 5Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea[J]. J Am Acad Der- matol, 2004, 50 (6): 907-912.
  • 6Elias PM, Hatano Y, Williams ML. Basis for the barrier abnor- mality in atopic dermatitis: outside-inside-outside pathogenic mechanisms[J]. J Allergy Clin Immunol, 2008, 121(6): 1337- 1343.
  • 7Elias PM, Arbiser J, Brown BE, et al. Epidermal vascular en- dothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: implications for the pathogenesis of psori- asis[J]. Am J Pathol, 2008, 173(3): 689-699.
  • 8Denda M, Kitamura K, Elias PM, et al. trans-4-(Aminomethyl) cyclohexane carboxylic acid (T-AMCHA), an anti-fibrinolytic a- gent, accelerates barrier recovery and prevents the epidermal hy- perplasia induced by epidermal injury in hairless mice and hu- mans[J]. J Invest Dermatol,1997, 109(1): 84-90.
  • 9Katsuta Y, Yoshida Y, Kawai E, et al. trans-4-(Aminomethyl)cy- clohexane carboxylic acid methylamide (t-AMCHA methylamide) inhibits the physical interaction between urokinase-type plas- minogen activator and stratum corneum, and accelerates the re- covery of barrier function[J]. J Dermatol Sci, 2005, 40(3): 218- 220.
  • 10Del RJ. Advances in understanding and managing rosacea: part 1: connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vas- cular changes and facial erythema [J]. J Clin Aesthet Dermatol, 2012, 5(3): 16-25.

共引文献242

同被引文献85

引证文献9

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部